Nasdaq Regulation



William Slattery, CFA Vice President Listing Qualifications

Electronic Mail Only

February 13, 2019

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Division of Corporate Finance:

This is to certify that on February 12, 2019, The Nasdaq Stock Market (the "Exchange") received from TCR2 Therapeutics Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

Common Stock, par value \$0.0001 per share

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

William Sattery

